百时美施贵宝Bristol Myers Squibb（BMY）2025年第二季度财务业绩演示报告「NYSE」（英文版）（17页）.pdf

1、Not for Product Promotional UseQ2 2025 ResultsJuly 31,2025Not for Product Promotional UseQ2 2025 ResultsForward Looking Statements and Non-GAAP Financial Information 2This presentation contains statements about Bristol-Myers Squibb Companys(the“Company”)future financial results,plans,business develo

2、pment strategy,anticipated clinical trials,results and regulatory approvals that constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995.All statements that are not statements of historical facts are,or may be deemed

3、 to be,forward-looking statements.Actual results may differ materially from those expressed in,or implied by,these statements as a result of various factors,including,but not limited to:(i)new laws,government actions and regulations,including with respect to pricing controls and market access and th

4、e imposition of new tariffs,trade restrictions and export regulations,(ii)our ability to obtain,protect and maintain market exclusivity rights and enforce patents and other intellectual property rights,(iii)our ability to achieve expected clinical,regulatory and contractual milestones on expected ti

5、melines or at all,(iv)difficulties or delays in the development and commercialization of new products,(v)difficulties or delays in our clinical trials and the manufacturing,distribution and sale of our products,(vi)adverse outcomes in legal or regulatory proceedings,(vii)risks relating to acquisitio

6、ns,divestitures,alliances,joint ventures and other portfolio actions and(viii)political and financial instability,including changes in general economic conditions.These and other important factors are discussed in the Companys most recent annual report on Form 10-K and reports on Forms 10-Q and 8-K.